Corrigendum: Prediction of EGFR Mutation Status Based on 18F-FDG PET/CT Imaging Using Deep Learning-Based Model in Lung Adenocarcinoma

Guotao Yin,Ziyang Wang,Yingchao Song,Xiaofeng Li,Yiwen Chen,Lei Zhu,Qian Su,Dong Dai,Wengui Xu

DOI: https://doi.org/10.3389/fonc.2021.747316

IF: 4.7

2021-09-07

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.709137.].

oncology

What problem does this paper attempt to address?

Corrigendum: Predictive value of intratumoral-metabolic heterogeneity derived from 18F-FDG PET/CT in distinguishing microsatellite instability status of colorectal carcinoma

Li Zhang,Yu Liu,Ying Ding,Yinqian Deng,Huanyu Chen,Fan Hu,Jun Fan,Xiaoli Lan,Wei Cao

DOI: https://doi.org/10.3389/fonc.2023.1351842

IF: 4.7

2024-01-05

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2023.1065744.].

oncology
Prediction of EGFR Mutation Status Based on 18F-FDG PET/CT Imaging Using Deep Learning-Based Model in Lung Adenocarcinoma

Guotao Yin,Ziyang Wang,Yingchao Song,Xiaofeng Li,Yiwen Chen,Lei Zhu,Qian Su,Dong Dai,Wengui Xu

DOI: https://doi.org/10.3389/fonc.2021.709137

IF: 4.7

2021-07-22

Frontiers in Oncology

Abstract:Objective The purpose of this study was to develop a deep learning-based system to automatically predict epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma in 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). Methods Three hundred and one lung adenocarcinoma patients with EGFR mutation status were enrolled in this study. Two deep learning models (SE CT and SE PET ) were developed with Squeeze-and-Excitation Residual Network (SE-ResNet) module for the prediction of EGFR mutation with CT and PET images, respectively. The deep learning models were trained with a training data set of 198 patients and tested with a testing data set of 103 patients. Stacked generalization was used to integrate the results of SE CT and SE PET . Results The AUCs of the SE CT and SE PET were 0.72 (95% CI, 0.62–0.80) and 0.74 (95% CI, 0.65–0.82) in the testing data set, respectively. After integrating SE CT and SE PET with stacked generalization, the AUC was further improved to 0.84 (95% CI, 0.75–0.90), significantly higher than SE CT (p<0.05). Conclusion The stacking model based on 18 F-FDG PET/CT images is capable to predict EGFR mutation status of patients with lung adenocarcinoma automatically and non-invasively. The proposed model in this study showed the potential to help clinicians identify suitable advanced patients with lung adenocarcinoma for EGFR‐targeted therapy.

oncology
Correction: Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer

Abhishek Mahajan,Gurukrishna B,Shweta Wadhwa,Ujjwal Agarwal,Ujjwal Baid,Sanjay Talbar,Amit Kumar Janu,Vijay Patil,Vanita Noronha,Naveen Mummudi,Anil Tibdewal,J P Agarwal,Subhash Yadav,Rajiv Kumar Kaushal,Ameya Puranik,Nilendu Purandare,Kumar Prabhash

DOI: https://doi.org/10.37349/etat.2024.00248

Abstract:[This corrects the article DOI: 10.37349/etat.2023.00158.].
Prediction of EGFR mutation status in lung adenocarcinoma based on 18F-FDG PET/CT radiomic features

Jian-Ling Tan,Liang Xia,Su-Guang Sun,Hui Zeng,Di-Yu Lu,Xiao-Jie Cheng

2023-10-20

Abstract:The earlier identification of EGFR mutation status in lung adenocarcinoma patients is crucial for treatment decision-making. Radiomics, which involves high-throughput extraction of imaging features from medical images for quantitative analysis, can quantify tumor heterogeneity and assess tumor biology non-invasively. This field has gained attention from researchers in recent years. The aim of this study is to establish a model based on 18F-FDG PET/CT radiomic features to predict the epidermal growth factor receptor (EGFR) mutation status of lung adenocarcinoma and evaluate its performance. 155 patients with lung adenocarcinoma who underwent 18F-FDG PET/CT scans and EGFR gene detection before treatment were retrospectively analyzed. The LIFEx packages was used to perform 3D volume of interest (VOI) segmentation manually on DICOM images and extract 128 radiomic features. The Wilcoxon rank sum test and least absolute shrinkage and selection operator (LASSO) regression algorithm were applied to filter the radiomic features and establish models. The performance of the models was evaluated by the receiver operating characteristic (ROC) curve and the area under the curve (AUC). Among the models we have built, the radiomic model based on 18F-FDG PET/CT has the best prediction performance for EGFR gene mutation status, with an AUC of 0.90 (95% CI 0.84~0.96) in the training set and 0.79 (95% CI 0.64~0.94) in the test set. In conclusion, we have established a radiomics model based on 18F-FDG PET/CT, which has good predictive performance in identifying EGFR gene mutation status in lung adenocarcinoma patients.
Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning

Shuo Wang,Jingyun Shi,Zhaoxiang Ye,Di Dong,Dongdong Yu,Mu Zhou,Ying Liu,Olivier Gevaert,Kun Wang,Yongbei Zhu,Hongyu Zhou,Zhenyu Liu,Jie Tian

DOI: https://doi.org/10.1183/13993003.00986-2018

IF: 24.3

2019-01-11

European Respiratory Journal

Abstract:Epidermal growth factor receptor (EGFR) genotyping is critical for treatment guidelines such as the use of tyrosine kinase inhibitors in lung adenocarcinoma. Conventional identification of EGFR genotype requires biopsy and sequence testing which is invasive and may suffer from the difficulty of accessing tissue samples. Here, we propose a deep learning model to predict EGFR mutation status in lung adenocarcinoma using non-invasive computed tomography (CT). We retrospectively collected data from 844 lung adenocarcinoma patients with pre-operative CT images, EGFR mutation and clinical information from two hospitals. An end-to-end deep learning model was proposed to predict the EGFR mutation status by CT scanning. By training in 14 926 CT images, the deep learning model achieved encouraging predictive performance in both the primary cohort (n=603; AUC 0.85, 95% CI 0.83–0.88) and the independent validation cohort (n=241; AUC 0.81, 95% CI 0.79–0.83), which showed significant improvement over previous studies using hand-crafted CT features or clinical characteristics (p<0.001). The deep learning score demonstrated significant differences in EGFR-mutant and EGFR-wild type tumours (p<0.001). Since CT is routinely used in lung cancer diagnosis, the deep learning model provides a non-invasive and easy-to-use method for EGFR mutation status prediction.

respiratory system
Predicting EGFR Mutation Status in Lung Adenocarcinoma on CT Image Using Deep Learning.

Shuo Wang,Jingyun Shi,Zhaoxiang Ye,Di Dong,Dongdong Yu,Mu Zhou,Ying Liu,Olivier Gevaert,Kun Wang,Yongbei Zhu,Hongyu Zhou,Zhenyu Liu,Jie Tian

DOI: https://doi.org/10.1183/13993003.00986-2018

IF: 24.3

2019-01-01

European Respiratory Journal

Abstract:Epidermal growth factor receptor (EGFR) genotyping is critical for treatment guidelines such as the use of tyrosine kinase inhibitors in lung adenocarcinoma. Conventional identification of EGFR genotype requires biopsy and sequence testing which is invasive and may suffer from the difficulty of accessing tissue samples. Here, we propose a deep learning model to predict EGFR mutation status in lung adenocarcinoma using non-invasive computed tomography (CT). We retrospectively collected data from 844 lung adenocarcinoma patients with pre-operative CT images, EGFR mutation and clinical information from two hospitals. An end-to-end deep learning model was proposed to predict the EGFR mutation status by CT scanning. By training in 14926 CT images, the deep learning model achieved encouraging predictive performance in both the primary cohort (n=603; AUC 0.85, 95% CI 0.83-0.88) and the independent validation cohort (n=241; AUC 0.81, 95% CI 0.79-0.83), which showed significant improvement over previous studies using hand-crafted CT features or clinical characteristics (p<0.001). The deep learning score demonstrated significant differences in EGFR-mutant and EGFR-wild type tumours (p<0.001). Since CT is routinely used in lung cancer diagnosis, the deep learning model provides a non-invasive and easy-to-use method for EGFR mutation status prediction.
Corrigendum: Machine learning prediction model for post- hepatectomy liver failure in hepatocellular carcinoma: a multicenter study

Jitao Wang,Tianlei Zheng,Yong Liao,Shi Geng,Jinlong Li,Zhanguo Zhang,Dong Shang,Chengyu Liu,Peng Yu,Yifei Huang,Chuan Liu,Yanna Liu,Shanghao Liu,Mingguang Wang,Dengxiang Liu,Hongrui Miao,Shuang Li,Biao Zhang,Anliang Huang,Yewei Zhang,Xiaolong Qi,Shubo Chen

DOI: https://doi.org/10.3389/fonc.2023.1278295

IF: 4.7

2023-08-31

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.986867.].

oncology
Prediction of EGFR-TP53 genes co-mutations in patients with lung adenocarcinoma (LUAD) by 18F-FDG PET/CT radiomics

Shuheng Li,Yujing Hu,Congna Tian,Jiusong Luan,Xinchao Zhang,Qiang Wei,Xiaodong Li,Yanzhu Bian

DOI: https://doi.org/10.1007/s12094-024-03685-0

2024-09-09

Abstract:Purpose: This retrospective study was undertaken to assess the predictive efficacy of 18F-FDG PET/CT -derived radiomic features concerning the co-mutation status of epidermal growth factor receptor (EGFR) and TP53 in LUAD. Methods: A cohort of 150 LUAD patients underwent pretreatment 18F-FDG PET/CT scans with known mutation status of EGFR and TP53 were collected. The feature extraction based on their PET/CT images utilized the Pyradiomics package based on the 3D Slicer. The optimal radiomic features were selected through correlation analysis and the Gradient Boosting Decision Tree (GBDT) algorithm, followed by the construction of the radiomic model. The clinical model incorporated meaningful clinical variables, whereas the complex model integrated both the radiomic and clinical models. The area under the receiver operating characteristic curve (AUC) facilitated the comparison of prediction performance across the three models. The DCA gauged the clinical utility of these models. Results: The patient cohort was randomly allocated into a training set (n = 105) and a validation set (n = 45) in a 7:3 ratio. Eleven PET and eleven CT optimal radiomic features were selected to construct the radiomic model. The model showed a good ability to discriminate the co-occurrence of EGFR and TP53, with AUC equal to 0.850 in the training set, and 0.748 in the validation set, compared with 0.750 and 0.626 for the clinical model. The complex model exhibited the highest AUC values, with 0.880 and 0.794 in both sets, but there were no significant differences compared to the radiomic model. The DCA revealed favorable clinical value.
New research progress on 18F-FDG PET/CT radiomics for EGFR mutation prediction in lung adenocarcinoma: a review

Xinyu Ge,Jianxiong Gao,Rong Niu,Yunmei Shi,Xiaoliang Shao,Yuetao Wang,Xiaonan Shao

DOI: https://doi.org/10.3389/fonc.2023.1242392

IF: 4.7

2023-11-29

Frontiers in Oncology

Abstract:Lung cancer, the most frequently diagnosed cancer worldwide, is the leading cause of cancer-associated deaths. In recent years, significant progress has been achieved in basic and clinical research concerning the epidermal growth factor receptor (EGFR), and the treatment of lung adenocarcinoma has also entered a new era of individualized, targeted therapies. However, the detection of lung adenocarcinoma is usually invasive. 18F-FDG PET/CT can be used as a noninvasive molecular imaging approach, and radiomics can acquire high-throughput data from standard images. These methods play an increasingly prominent role in diagnosing and treating cancers. Herein, we reviewed the progress in applying 18F-FDG PET/CT and radiomics in lung adenocarcinoma clinical research and how these data are analyzed via traditional statistics, machine learning, and deep learning to predict EGFR mutation status, all of which achieved satisfactory results. Traditional statistics extract features effectively, machine learning achieves higher accuracy with complex algorithms, and deep learning obtains significant results through end-to-end methods. Future research should combine these methods to achieve more accurate predictions, providing reliable evidence for the precision treatment of lung adenocarcinoma. At the same time, facing challenges such as data insufficiency and high algorithm complexity, future researchers must continuously explore and optimize to better apply to clinical practice.

oncology
Predicting EGFR Mutation Subtypes in Lung Adenocarcinoma Using 18F-FDG PET/CT Radiomic Features

Qiufang Liu,Dazhen Sun,Nan Li,Jinman Kim,Dagan Feng,Gang Huang,Lisheng Wang,Shaoli Song

DOI: https://doi.org/10.21037/tlcr.2020.04.17

2020-01-01

Translational Lung Cancer Research

Abstract:Background: Identification of epidermal growth factor receptor (EGFR) mutation types is crucial before tyrosine kinase inhibitors (TKIs) treatment. Radiomics is a new strategy to noninvasively predict the genetic status of cancer. In this study, we aimed to develop a predictive model based on F-18-fluorodeoxyglucose positron emission tomography-computed tomography (F-18-FDG PET/CT) radiomic features to identify the specific EGFR mutation subtypes. Methods: We retrospectively studied F-18-FDG PET/CT images of 148 patients with isolated lung lesions, which were scanned in two hospitals with different CT scan setting (slice thickness: 3 and 5 mm, respectively). The tumor regions were manually segmented on PET/CT images, and 1,570 radiomic features (1,470 from CT and 100 from PET) were extracted from the tumor regions. Seven hundred and ninety-four radiomic features insensitive to different CT settings were first selected using the Mann white U test, and collinear features were further removed from them by recursively calculating the variation inflation factor. Then, multiple supervised machine learning models were applied to identify prognostic radiomic features through: (I) a multi-variate random forest to select features of high importance in discriminating different EGFR mutation status; (II) a logistic regression model to select features of the highest predictive value of the EGFR subtypes. The EGFR mutation predicting model was constructed from prognostic radiomic features using the popular Xgboost machine-learning algorithm and validated using 3-fold cross-validation. The performance of predicting model was analyzed using the receiver operating characteristic curve (ROC) and measured with the area under the curve (AUC). Results: Two sets of prognostic radiomic features were found for specific EGFR mutation subtypes: 5 radiomic features for EGFR exon 19 deletions, and 5 radiomic features for EGFR exon 21 L858R missense. The corresponding radiomic predictors achieved the prediction accuracies of 0.77 and 0.92 in terms of AUC, respectively. Combing these two predictors, the overall model for predicting EGFR mutation positivity was also constructed, and the AUC was 0.87. Conclusions: In our study, we established predictive models based on radiomic analysis of F-18-FDG PET/CT images. And it achieved a satisfying prediction power in the identification of EGFR mutation status as well as the certain EGFR mutation subtypes in lung cancer.
Optimal <SUP>18</SUP>F-FDG PET/CT radiomics model development for predicting EGFR mutation status and prognosis in lung adenocarcinoma: a multicentric study

Yan Zuo,Qiufang Liu,Nan Li,Panli Li,Jianping Zhang,Shaoli Song

DOI: https://doi.org/10.3389/fonc.2023.1173355

IF: 4.7

2023-01-01

Frontiers in Oncology

Abstract:PurposeTo develop and interpret optimal predictive models to identify epidermal growth factor receptor (EGFR) mutation status and subtypes in patients with lung adenocarcinoma based on multicentric F-18-FDG PET/CT data, and further construct a prognostic model to predict their clinical outcome. MethodsThe F-18-FDG PET/CT imaging and clinical characters of 767 patients with lung adenocarcinoma from 4 cohorts were collected. Seventy-six radiomics candidates using cross-combination method to identity EGFR mutation status and subtypes were built. Further, Shapley additive explanations and local interpretable model-agnostic explanations were used for optimal models' interpretation. Moreover, in order to predict the overall survival, a multivariate Cox proportional hazard model based on handcrafted radiomics features and clinical characteristics was constructed. The predictive performance and clinical net benefit of the models were evaluated via area under receiver operating characteristic (AUC), C-index and decision curve analysis. ResultsAmong the 76 radiomics candidates, light gradient boosting machine classifier (LGBM) combined with recursive feature elimination wrapped LGBM feature selection method achieved best performance in predicting EGFR mutation status (AUC reached 0.80, 0.61, 0.71 in the internal test cohort and two external test cohorts, respectively). And extreme gradient boosting classifier combined with support vector machine feature selection method achieved best performance in predicting EGFR subtypes (AUC reached 0.76, 0.63, 0.61 in the internal test cohort and two external test cohorts, respectively). The C-index of the Cox proportional hazard model achieved 0.863. ConclusionsThe integration of cross-combination method and the external validation from multi-center data achieved a good prediction and generalization performance in predicting EGFR mutation status and its subtypes. The combination of handcrafted radiomics features and clinical factors achieved good performance in predicting prognosis. With the urgent needs of multicentric F-18-FDG PET/CT trails, robust and explainable radiomics models have great potential in decision making and prognosis prediction of lung adenocarcinoma.
Corrigendum: Construction and Validation of a Lung Cancer Risk Prediction Model for Non-Smokers in China

Lan-Wei Guo,Zhang-Yan Lyu,Qing-Cheng Meng,Li-Yang Zheng,Qiong Chen,Yin Liu,Hui-Fang Xu,Rui-Hua Kang,Lu-Yao Zhang,Xiao-Qin Cao,Shu-Zheng Liu,Xi-Bin Sun,Jian-Gong Zhang,Shao-Kai Zhang

DOI: https://doi.org/10.3389/fonc.2022.871848

IF: 4.7

2022-03-03

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.766939.].

oncology
Correction: Solitary Ground-Glass Opacity Nodules of Stage IA Pulmonary Adenocarcinoma: Combination of 18F-FDG PET/CT and High-Resolution Computed Tomography Features to Predict Invasive Adenocarcinoma.

Jun Zhou,Yanli Li,Yiqiu Zhang,Guobing Liu,Hui Tan,Yan Hu,Jie Xiao,Hongcheng Shi

DOI: https://doi.org/10.18632/oncotarget.26671

2019-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.15577.].
18F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography-Based Radiomic Features for Prediction of Epidermal Growth Factor Receptor Mutation Status and Prognosis in Patients with Lung Adenocarcinoma

Bin Yang,Heng-Shan Ji,Chang-Sheng Zhou,Hao Dong,Lu Ma,Ying-Qian Ge,Chao-Hui Zhu,Jia-He Tian,Long-Jiang Zhang,Hong Zhu,Guang-Ming Lu

DOI: https://doi.org/10.21037/tlcr-19-592

2020-01-01

Translational Lung Cancer Research

Abstract:Background: To investigate whether radiomic features from (F-18)-fluorodeoxyglucose positron emission tomography/computed tomography [(F-18)-FDG PET/CT] can predict epidermal growth factor receptor (EGFR) mutation status and prognosis in patients with lung adenocarcinoma. Methods: One hundred and seventy-four consecutive patients with lung adenocarcinoma underwent (F-18)-FDG PET/CT and EGFR gene testing were retrospectively analyzed. Radiomic features combined with clinicopathological factors to construct a random forest (RF) model to identify EGFR mutation status. The mutant/wild-type model was trained on a training group (n=139) and validated in an independent validation group (n=35). The second RF classifier predicting the 19/21 mutation site was also built and evaluated in an EGFR mutation subset (training group, n=80; validation group, n=25). Radiomic score and 5 clinicopathological factors were integrated into a multivariate Cox proportional hazard (CPH) model for predicting overall survival (OS). AUC (the area under the receiver characteristic curve) and C-index were calculated to evaluate the model's performance. Results: Of 174 patients, 109 (62.6%) harbored EGFR mutations, 21L858R was the most common mutation type [55.9% (61/109)]. The mutant/wild-type model was identified in the training (AUC, 0.77) and validation (AUC, 0.71) groups. The 19/21 mutation site model had an AUC of 0.82 and 0.73 in the training and validation groups, respectively. The C-index of the CPH model was 0.757. The survival time between targeted therapy and chemotherapy for patients with EGFR mutations was significantly different (P=0.03). Conclusions: Radiomic features based on (F-18)-FDG PET/CT combined with clinicopathological factors could reflect genetic differences and predict EGFR mutation type and prognosis.
Corrigendum: Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells

Zhenyu Wei,Jiayu Xu,Chengkui Zhao,Min Zhang,Nan Xu,Liqing Kang,Xiaoyan Lou,Lei Yu,Weixing Feng

DOI: https://doi.org/10.3389/fimmu.2024.1379325

IF: 7.3

2024-02-08

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1273507.].

immunology
Predictive value of 18F-FDG PET/CT radiomics for EGFR mutation status in non-small cell lung cancer: a systematic review and meta-analysis

Ning Ma,Weihua Yang,Qiannan Wang,Caozhe Cui,Yiyi Hu,Zhifang Wu

DOI: https://doi.org/10.3389/fonc.2024.1281572

IF: 4.7

2024-02-01

Frontiers in Oncology

Abstract:Objective: This study aimed to evaluate the value of 18 F-FDG PET/CT radiomics in predicting EGFR gene mutations in non-small cell lung cancer by meta-analysis. Methods: The PubMed, Embase, Cochrane Library, Web of Science, and CNKI databases were searched from the earliest available date to June 30, 2023. The meta-analysis was performed using the Stata 15.0 software. The methodological quality and risk of bias of included studies were assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 and Radiomics Quality Score criteria. The possible causes of heterogeneity were analyzed by meta-regression. Results: A total of 17 studies involving 3763 non-small cell lung cancer patients were finally included. We analyzed 17 training cohorts and 10 validation cohorts independently. Within the training cohort, the application of 18 F-FDG PET/CT radiomics in predicting EGFR mutations in NSCLC demonstrated a sensitivity of 0.76 (95% CI: 0.70-0.81) and a specificity of 0.78 (95% CI: 0.74-0.82), accompanied by a positive likelihood ratio of 3.5 (95% CI:3.0-4.2), a negative likelihood ratio of 0.31 (95% CI: 0.24-0.39), a diagnostic odds ratio of 11.0 (95% CI: 8.0-16.0), and an area under the curve (AUC) of 0.84 (95% CI: 0.80-0.87). In the validation cohort, the values included a sensitivity of 0.76 (95% CI: 0.67-0.83), a specificity of 0.75 (95% CI: 0.68-0.80), a positive likelihood ratio of 3.0 (95% CI:2.4-3.8), a negative likelihood ratio of 0.32 (95% CI: 0.24-0.44), a diagnostic odds ratio of 9 (95% CI: 6-15), and an AUC of 0.82 (95% CI: 0.78-0.85). The average Radiomics Quality Score (RQS) across studies was 10.47 ± 4.72. Meta-regression analysis identifies the application of deep learning and regions as sources of heterogeneity. Conclusion: 18 F-FDG PET/CT radiomics may be useful in predicting mutation status of the EGFR gene in non-small cell lung cancer. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42022385364.

oncology
Predicting EGFR mutation status in lung adenocarcinoma presenting as ground-glass opacity: utilizing radiomics model in clinical translation

Bo Cheng,Hongsheng Deng,Yi Zhao,Junfeng Xiong,Peng Liang,Caichen Li,Hengrui Liang,Jiang Shi,Jianfu Li,Shan Xiong,Ting Lai,Zhuxing Chen,Jianrong Wu,Tianyi Qian,Wenjing Huan,Man Tat Alexander Ng,Jianxing He,Wenhua Liang

DOI: https://doi.org/10.1007/s00330-022-08673-y

IF: 7.034

2022-03-29

European Radiology

Abstract:This study aimed to establish a non-invasive radiomics model based on computed tomography (CT), with favorable sensitivity and specificity to predict EGFR mutation status in GGO-featured lung adenocarcinoma subsequently guiding the administration of targeted therapy.

radiology, nuclear medicine & medical imaging
Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Jianlin Xu,Haitang Yang,Bo Jin,Yuqing Lou,Yanwei Zhang,Xueyan Zhang,Hua Zhong,Huiming Wang,Dan Wu,Baohui Han

DOI: https://doi.org/10.1038/srep38270

IF: 4.6

2016-01-01

Scientific Reports

Abstract:Scientific Reports 6: Article number: 36371; published online: 04 November 2016; updated: 01 December 2016
Correlations Study Between 18 F-FDG PET/CT Metabolic Parameters Predicting Epidermal Growth Factor Receptor Mutation Status and Prognosis in Lung Adenocarcinoma.

Bin Yang,Qing Gen Wang,Mengjie Lu,Yingqian Ge,Yu Jun Zheng,Hong Zhu,Guangming Lu

DOI: https://doi.org/10.3389/fonc.2019.00589

IF: 4.7

2019-01-01

Frontiers in Oncology

Abstract:Purpose: This study assessed the ability of metabolic parameters from (18)Fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG PET/CT) and clinicopathological data to predict epidermal growth factor receptor (EGFR) expression/mutation status in patients with lung adenocarcinoma and to develop a prognostic model based on differences in EGFR expression status, to enable individualized targeted molecular therapy. Patients and Methods: Metabolic parameters and clinicopathological data from 200 patients diagnosed with lung adenocarcinoma between July 2009 and November 2016, who underwent F-18-FDG PET/CT and EGFR mutation testing, were retrospectively evaluated. Multivariate logistic regression was applied to significant variables to establish a prediction model for EGFR mutation status. Overall survival for both mutant and wild-type EGFR was analyzed to establish a multifactor Cox regression model. Results: Of the 200 patients, 115 (58%) exhibited EGFR mutations and 85 (42%) were wild-type. Among selected metabolic parameters, metabolic tumor volume (MTV) demonstrated a significant difference between wild-type and mutant EGFR mutation status, with an area under the receiver operating characteristic curve (AUC) of 0.60, which increased to 0.70 after clinical data (smoking status) were combined. Survival analysis of wild-type and mutant EGFR yielded mean survival times of 34.451 (95% CI 28.654-40.249) and 53.714 (95% CI 44.331-63.098) months, respectively. Multivariate Cox regression revealed that mutation type, tumor stage, and thyroid transcription factor-1 (TTF-1) expression status were the main factors influencing patient prognosis. The hazard ratio for mutant EGFR was 0.511 (95% CI 0.303-0.862) times that of wild-type, and the risk of death was lower for mutant EGFR than for wild-type. The risk of death was lower in TTF-1-positive than in TTF-1-negative patients. Conclusion: F-18-FDG PET/CTmetabolic parameters combined with clinicopathological data demonstrated moderate diagnostic efficacy in predicting EGFR mutation status and were associated with prognosis inmutant and wild-type EGFR non-small-cell lung cancer (NSCLC), thus providing a reference for individualized targeted molecular therapy.
Corrigendum: Identification of an autophagy-related 12-lncRNA signature and evaluation of NFYC-AS1 as a pro-cancer factor in lung adenocarcinoma

Fang Tong,Lifa Xu,Sheng Xu,Mingming Zhang

DOI: https://doi.org/10.3389/fgene.2022.1050296

IF: 3.7

2022-10-25

Frontiers in Genetics

Abstract:[This corrects the article DOI: 10.3389/fgene.2022.834935.].

genetics & heredity

Corrigendum: Prediction of EGFR Mutation Status Based on 18F-FDG PET/CT Imaging Using Deep Learning-Based Model in Lung Adenocarcinoma

Corrigendum: Predictive value of intratumoral-metabolic heterogeneity derived from 18F-FDG PET/CT in distinguishing microsatellite instability status of colorectal carcinoma

Prediction of EGFR Mutation Status Based on 18F-FDG PET/CT Imaging Using Deep Learning-Based Model in Lung Adenocarcinoma

Correction: Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer

Prediction of EGFR mutation status in lung adenocarcinoma based on 18F-FDG PET/CT radiomic features

Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning

Predicting EGFR Mutation Status in Lung Adenocarcinoma on CT Image Using Deep Learning.

Corrigendum: Machine learning prediction model for post- hepatectomy liver failure in hepatocellular carcinoma: a multicenter study

Prediction of EGFR-TP53 genes co-mutations in patients with lung adenocarcinoma (LUAD) by 18F-FDG PET/CT radiomics

New research progress on 18F-FDG PET/CT radiomics for EGFR mutation prediction in lung adenocarcinoma: a review

Predicting EGFR Mutation Subtypes in Lung Adenocarcinoma Using 18F-FDG PET/CT Radiomic Features

Optimal <SUP>18</SUP>F-FDG PET/CT radiomics model development for predicting EGFR mutation status and prognosis in lung adenocarcinoma: a multicentric study

Corrigendum: Construction and Validation of a Lung Cancer Risk Prediction Model for Non-Smokers in China

Correction: Solitary Ground-Glass Opacity Nodules of Stage IA Pulmonary Adenocarcinoma: Combination of 18F-FDG PET/CT and High-Resolution Computed Tomography Features to Predict Invasive Adenocarcinoma.

18F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography-Based Radiomic Features for Prediction of Epidermal Growth Factor Receptor Mutation Status and Prognosis in Patients with Lung Adenocarcinoma

Corrigendum: Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells

Predictive value of 18F-FDG PET/CT radiomics for EGFR mutation status in non-small cell lung cancer: a systematic review and meta-analysis

Predicting EGFR mutation status in lung adenocarcinoma presenting as ground-glass opacity: utilizing radiomics model in clinical translation

Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Correlations Study Between 18 F-FDG PET/CT Metabolic Parameters Predicting Epidermal Growth Factor Receptor Mutation Status and Prognosis in Lung Adenocarcinoma.

Corrigendum: Identification of an autophagy-related 12-lncRNA signature and evaluation of NFYC-AS1 as a pro-cancer factor in lung adenocarcinoma